AlloVirALVR
Market Cap: 90.4M
About: AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Employees: 112
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
19,950% more call options, than puts
Call options by funds: $401K | Put options by funds: $2K
28% more capital invested
Capital invested by funds: $28.5M [Q4 2023] → $36.4M (+$7.93M) [Q1 2024]
6.5% more ownership
Funds ownership: 36.72% [Q4 2023] → 43.22% (+6.5%) [Q1 2024]
6% less funds holding
Funds holding: 83 [Q4 2023] → 78 (-5) [Q1 2024]
21% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 28
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Research analyst outlook
We haven’t received any recent analyst ratings for ALVR.